Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year High – Time to Buy?

Bicara Therapeutics Inc. (NASDAQ:BCAXGet Free Report)’s stock price hit a new 52-week high on Wednesday . The company traded as high as $28.08 and last traded at $26.11, with a volume of 2883 shares. The stock had previously closed at $25.19.

Analyst Upgrades and Downgrades

BCAX has been the topic of a number of recent analyst reports. TD Cowen assumed coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. Cantor Fitzgerald initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating for the company. Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price objective on the stock. Morgan Stanley assumed coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price target for the company. Finally, RODMAN&RENSHAW raised Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Bicara Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $43.33.

Read Our Latest Report on BCAX

Bicara Therapeutics Trading Up 1.0 %

Insider Buying and Selling

In related news, major shareholder James E. Flynn purchased 70,000 shares of Bicara Therapeutics stock in a transaction that occurred on Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, with a total value of $1,260,000.00. Following the completion of the transaction, the insider now owns 897,587 shares of the company’s stock, valued at approximately $16,156,566. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, major shareholder James E. Flynn purchased 70,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, with a total value of $1,260,000.00. Following the acquisition, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was acquired at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the purchase, the director now directly owns 4,303,418 shares in the company, valued at approximately $77,461,524. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Bicara Therapeutics Company Profile

(Get Free Report)

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

Featured Articles

Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.